Substantial progress has been made in our understanding of the
biology of pancreatic cancer, and advances in patients management have also taken place. Evidence is beginning to show that screening first-degree relatives of individuals with several family members affected by pancreatic cancer can identify non-invasive precursors of this malignant disease. The incidence of and number of deaths caused by pancreatic tumours have been gradually rising, even as incidence and mortality of other common cancers have been declining.
Liver cancer is classified into primary and metastatic liver cancer. In Japan, hepatocellular carcinoma (HCC) accounts for about 95% and intrahepatic cholangiocarcinoma for about 4% of primary liver cancer.
In the current study we have treated pancreatic cancer cell line PANC-1 and liver cancer cell line hepG2 with different concentrations of Absogen to study the induction f apoptosis mediated cell death.
Absogen induced the apoptotic cell death in both pancreatic cancer cell line and liver cancer cell line in a dose dependent manner. The effect on pancreatic cancer cell line PANC-1 was more evident in comparison to liver cancer cell line hepG2. Pancreatic cancer falls under the category of neuroendocrine tumor system and Absogen was able to induce the in vitro apoptosis in the cells even at a very low concentration of 5 ug/ml which further enhanced upto 53 percent with higher doses. The data clearly indicates Absogen as a potential future target for drg development against pancreatic and other neuroendocrine cancers.